COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO

被引：1
|
作者：
Salinas-Escudero, G. [1 ]
Contreras-Hernandez, I [2 ]
Mould-Quevedo, J. [3 ]
机构：
[1] Hosp Infantil Mexico Fed Gomez, Mexico City, DF, Mexico
[2] Social Secur Mexican Inst, Mexico City, DF, Mexico
[3] Pfizer Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75353-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF PAZOPANIB VERSUS SUNITINIB AND BEVACIZUMAB ASSOCIATED TO INTERFERON ALPHA AS FIRST LINE TREATMENTS FOR METASTATIC RENAL CELL CARCINOMA
    Pepe, C.
    Paladini, L.
    Sedlmayer, C.
    Machado, M.
    VALUE IN HEALTH, 2012, 15 (04) : A218 - A218
  • [22] Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy A Cost-Minimization Analysis
    Ravasio, Roberto
    Ortega, Cinzia
    Sabbatini, Roberto
    Porta, Camillo
    CLINICAL DRUG INVESTIGATION, 2011, 31 (07) : 507 - 517
  • [23] Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in ItalyA Cost-Minimization Analysis
    Roberto Ravasio
    Cinzia Ortega
    Roberto Sabbatini
    Camillo Porta
    Clinical Drug Investigation, 2011, 31 : 507 - 517
  • [24] Economic evaluation of sunitinib vs. interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Negrier, S.
    Remak, E.
    Brown, R.
    Kim, S. T.
    Charbonneau, C.
    Motzer, R. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 303 - 303
  • [25] Metastatic renal cell carcinoma: a comparative effectiveness assessment of first-line bevacizumab plus Interferon alpha-2a vs sunitinib
    Mickisch, G. H.
    Schwander, B.
    Walzer, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 437 - 437
  • [26] A COMPARATIVE EFFECTIVENESS ASSESSMENT OF FIRST-LINE BEVACIZUMAB plus INTERFERON ALPHA-2A VS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA
    Mickisch, G. H.
    Schwander, B.
    Escudier, B.
    Bellmunt, J.
    Maroto, P.
    Porta, C.
    Walzer, S.
    Siebert, U.
    VALUE IN HEALTH, 2009, 12 (07) : A258 - A258
  • [27] Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
    Chee, Cheng Ean
    Khara, Jasmeet Singh
    Cheong, John
    Fong, Jek
    Sivanesan, Sivabalan
    Choy, Jian Yi
    Hu, Meibo
    Viswambaram, Amrita
    Toh, Han Chong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 631 - 641
  • [28] Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
  • [30] Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
    Emiliano Calvo Aller
    Pablo Maroto
    Noémi Kreif
    José Luis González Larriba
    Marta López-Brea
    Daniel Castellano
    Belén Martí
    Silvia Díaz Cerezo
    Clinical and Translational Oncology, 2011, 13 : 869 - 877
12345